An interventional study of EVLA 1940 nm and EVLA 1470 nm in Varicose Veins, sponsored by Clinique Pasteur. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-06.
Sponsored by Clinique Pasteur · Not applicable, Interventional, and Treatment
The goal of this clinical trial is to compare efficacy of two wavelength for EndoVenous Laser Ablation (EVLA) in treatment of varicose veins of the lower limbs.
The main questions it aims to answers are :
After laser ablation patients will be followed during 5 years for clinical evaluation, recording potential treatment complications and quality of life evaluation.
Researchers will compare strategy 1(EVLA with an endovenous laser at 1940 nm) vs strategy 2 (EVLA with an endovenous laser at 1470 nm) in varicose veins treatment to see if efficacy of treatment is not reduce, and to see if complications of EVLA treatment can be reduced.
226 studies on the registry are indexed under Varicose Veins; 30 are open to participants now.
This study's planned enrollment of 280 is above the median of 101 across 154 interventional studies indexed under Varicose Veins.
Browse Varicose Veins studies →Clinique Pasteur is the lead sponsor of 15 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Endovenous laser at 1940 nm
Procedure: EVLA 1940 nm
Endovenous laser at 1470 nm
Procedure: EVLA 1470 nm
Treatment of varicose veins by endothermic ablation with an endovenous laser at 1940 nm
Treatment of varicose veins by endothermic ablation with an endovenous laser at 1470 nm
Anatomical success
Closure of the target vein
Time frame: At 5 years
VAS Pain
Visual Analogue Scale (0-100 mm); higher is worse
Time frame: Day 0, Day 8, Month 6, Year 1, Year 2, Year 3, Year 4, Year 5
Adverse Events
Adverse events related to endovenous treatment
Time frame: Day 0, Day 8, Month 6, Year 1, Year 2, Year 3, Year 4, Year 5
Venous Clinical Severity
Venous Clinical Severity Score (VCSS) ; score between 0 to 30; higher is worse
Time frame: Day 0, Day 8, Month 6, Year 1, Year 2, Year 3, Year 4, Year 5
Symptoms
VEINES Sym (VEnous INsufficiency Epidemiologic and Economic Study - Symptoms) questionnaire
Time frame: Day 0, Month 6, Year 1, Year 2, Year 3, Year 4, Year 5
Patient quality of life (1)
VEINES Sym (VEnous INsufficiency Epidemiologic and Economic Study - quality of life ) questionnaire
Time frame: Day 0, Month 6, Year 1, Year 2, Year 3, Year 4, Year 5
Patient quality of life (2)
EuroQol-5 Dimension (EQ5D) Quality of life survey
Time frame: Day 0, Month 6, Year 1, Year 2, Year 3, Year 4, Year 5
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Clinique Pasteur